GLP-1 Drug Manufacturers & Compounded Options

Last reviewed: May 28, 2026

Last updated: May 28, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

GLP-1 receptor agonists are manufactured by major pharmaceutical companies including Novo Nordisk, Eli Lilly, and Viking Therapeutics, with medications available through both brand-name and licensed compounded-pharmacy channels. As of 2024, compounded semaglutide and tirzepatide represent an accessible alternative pathway for patients seeking cost-effective access.

Selecting a GLP-1 medication involves more than choosing a manufacturer—it requires understanding regulatory pathways, cost structures, and individual physiological factors. PlexusDx emphasizes precision wellness by helping patients evaluate options through clinical evidence and, where appropriate, genetic context that may support more informed provider conversations.

Major Pharmaceutical Manufacturers and Their GLP-1 Portfolios

Novo Nordisk leads the GLP-1 market with semaglutide products: Ozempic (diabetes), Wegovy (weight management), and Rybelsus (oral form). The company maintains the largest market share and extensive clinical trial data supporting efficacy and safety profiles across diverse patient populations.

Eli Lilly produces tirzepatide (Mounjaro for diabetes, Zepbound for weight management) and dulaglutide (Trulicity). Lilly's dual GIP/GLP-1 receptor agonist mechanism represents a distinct pharmacological approach with comparable efficacy demonstrated in randomized controlled trials published in major medical journals.

Branded vs. Compounded GLP-1 Pathways: Regulatory and Access Differences

Branded GLP-1 medications undergo full FDA approval and carry standardized formulations. Compounded GLP-1 medications are prepared by licensed 503A pharmacies under pharmacy compounding regulations, offering flexibility in dosing and delivery but without formal FDA approval processes. Both pathways serve distinct patient needs and access situations.

Characteristic	Branded GLP-1s	Compounded GLP-1s
Manufacturer	Major pharma (Novo Nordisk, Lilly, Viking)	Licensed 503A compounding pharmacies
FDA Status	FDA-approved formulations	Pharmacy-compounded, not FDA-approved
Dosing Flexibility	Fixed, standard doses	Customizable doses and delivery
Cost Range	$900–$1,400/month (typically)	$129-$389/mo (varies by formulation)
Insurance Coverage	Often covered; requires prior auth	Limited insurance coverage; cash-pay common
Quality Standards	GMP manufacturing; extensive QA	USP <797> sterile compounding standards

Emerging Manufacturers and Novel GLP-1 Mechanisms

Viking Therapeutics is developing VK2735, a dual GIP/GLP-1 receptor agonist currently in late-stage trials, with data suggesting weight loss comparable to tirzepatide. Other companies including Structure Therapeutics and Viking are exploring oral formulations and novel receptor combinations to expand the therapeutic landscape.

Retatrutide, developed by Eli Lilly, represents a triple GIP/GLP-1/GCG receptor agonist in clinical development, showing enhanced weight loss in early studies. These emerging agents suggest the GLP-1 market will continue diversifying, offering patients and providers additional mechanism-based options for personalized treatment.

Genetic Biomarkers and Individual Response Variation: A Clinical Consideration

Response to GLP-1 medications varies substantially between individuals, in part due to genetic variation in peptide pathway genes. Key variants in GLP1R, GIPR, FTO, and MC4R influence appetite signaling, metabolic efficiency, and weight regulation—factors that may contextualize individual treatment response.

PlexusDx's Precision Peptide Genetic Test may help identify predispositions in these peptide pathways, providing context for provider conversations about medication selection. This test does not predict exact medication response but may support a more informed, individualized discussion about which GLP-1 approach aligns with a patient's physiological profile and clinical goals.

How to Evaluate Manufacturer and Formulation Options with Your Provider

When selecting a GLP-1 medication, discuss with your provider: mechanism of action (single vs. dual GIP/GLP-1), clinical evidence in your specific population, cost and insurance coverage, dosing flexibility needs, and any contraindications or comorbidities. This conversation should prioritize efficacy, safety, and personal access factors rather than manufacturer brand alone.

Compounded semaglutide and tirzepatide from licensed 503A pharmacies offer cost-effective alternatives when branded options are inaccessible. PlexusDx provides compounded options ranging from $129/mo to $349/mo, allowing providers and patients to optimize treatment within realistic budget constraints while maintaining quality and safety standards.

How PlexusDx Supports a More Personalized Approach

PlexusDx contextualizes GLP-1 manufacturer and formulation choices through precision-wellness principles. Our genetic testing in peptide pathway variants—GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313—may help provide context about individual biological predispositions to GLP-1 response. This information should always be interpreted with a qualified healthcare provider.

The Precision Peptide Genetic Test ($99 add-on or $298 standalone) reveals predispositions in peptide signaling pathways relevant to appetite, metabolic regulation, and GLP-1 receptor function. These genetic insights do not predict exact medication response or guarantee outcomes but may support a more nuanced conversation about which GLP-1 approach aligns with your individual physiology.

Whether selecting a branded GLP-1 from a major manufacturer or exploring compounded options through PlexusDx, pairing this decision with genetic biomarker context can support a more informed provider conversation. Understanding both your manufacturer options and your individual genetic predispositions empowers more personalized, evidence-based treatment planning.

How Your Genetics Relate to GLP-1 Pathways

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month, or $298 standalone) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers seven prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Oral is $349/mo month-to-month, or from $279/mo on the 6-month plan. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Frequently Asked Questions

Which products does this article assign to Novo Nordisk versus Eli Lilly?

The article assigns semaglutide products to Novo Nordisk, naming Ozempic for diabetes, Wegovy for weight management and Rybelsus in oral form, and assigns tirzepatide to Eli Lilly as Mounjaro for diabetes and Zepbound for weight management, along with dulaglutide sold as Trulicity. It describes Lilly's dual GIP and GLP-1 mechanism as a distinct pharmacological approach.

What does this post's comparison table say about the FDA status of compounded GLP-1s?

The table states plainly that branded GLP-1s are FDA-approved formulations while compounded GLP-1s are pharmacy-compounded and not FDA-approved. It pairs that with dosing flexibility as the compounded advantage, limited insurance coverage and cash payment as the norm, and USP Chapter 797 sterile compounding standards as the applicable quality framework.

Which investigational agents does this article name as still in development?

The article names VK2735 from Viking Therapeutics, described as a dual GIP and GLP-1 agonist in late-stage trials, and retatrutide from Eli Lilly, a triple GIP, GLP-1 and glucagon receptor agonist in clinical development. Both are investigational rather than approved, and PlexusDx does not sell retatrutide. Structure Therapeutics is also mentioned as working on oral formulations.

What does this post say patients should actually discuss when choosing between options?

The post says the conversation with a provider should cover mechanism of action, meaning single versus dual receptor activity, clinical evidence in the patient's own population, cost and insurance coverage, dosing flexibility needs, and any contraindications or comorbidities. It argues the decision should turn on efficacy, safety and access rather than manufacturer brand alone.

What quality standard does this article attribute to compounded preparations?

The article attributes USP Chapter 797 sterile compounding standards to compounded preparations, contrasted with GMP manufacturing and extensive quality assurance for branded products. It says compounded medications come from licensed 503A pharmacies operating under pharmacy compounding regulations, which offer dosing and delivery flexibility but sit outside the formal FDA approval process.

Related Reading

• History Of Glp 1 Drugs Plexusdx
• Glp 1 Agonist Drugs
• Glp 1 Drugs List
• Drugs Glp 1

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.